RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry

As Rainbow Coral Corp. (OTCBB:RBCC) works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.

Pharmaceutical compounding is a form of personalized medicine in which a pharmacist creates a particular pharmaceutical product to suit a patient’s unique needs. To accomplish that, compounding pharmacists combine or process various ingredients using sterile tools.

RBCC is already in the drug-delivery business. The company formed a joint venture with TheraKine, Ltd., to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of the prescription drug Naltrexone. As demand for personalized medicine grows, now the company is looking to branch out.

“We’re exploring new ways to leverage our expertise in topical and injectable drug delivery protocols,” said RBCC CEO Kimberly Palmer. “The market for personalized medicine, including compounding, continues to expand as demand rises. We believe there is a potentially lucrative opportunity here for RBCC to become an end-to-end provider of sterile compounding products.”

RBCC's biotech division, Rainbow BioSciences, is working to capitalize on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Valeant Pharmaceuticals International (NYSE: VRX).

For more information on RBCC’s other biotech initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150602005771/en/